top of page

National Collaboration

MCBv2.png

Prof. dr hab. Grzegorz Dubin

Protein Crystallography Research Group

MaÅ‚opolska Center of Biotechnology
Jagiellonian University

Krakow, Poland

wchuj_75.png

Prof. dr hab. Tad Holak

Chemical Biology and Drug Discovery

Faculty of Chemistry

Jagiellonian University

Krakow, Poland

DMB-JU_edited.jpg

Prof. dr hab. Jósef Dulak

Department of Medical Biotechnology

Faculty of Biochemistry, Biophysics and Biotechnology

Krakow, Poland

International Collaboration

img-logo-2x-new.png

Prof. Nathanael Gray

Dana-Farber Cancer Institute

Boston, USA

Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and Professor of Cancer Biology at Dana-Farber Cancer Institute. His work focuses on synthetic chemistry and novel small molecule inhibitors.

ManRos-Perha logos.png

Prof. Laurent Meijer

ManRos Therapeutics

Perha Pharmaceuticals

Roscoff, France

One of the world’s leading experts in disease-relevant kinases and their pharmacological inhibitors. Dr. Meijer has generated more than 40 patents, published over 340 articles, edited 6 books and has been working with three Nobel Prize recipients. In 1985-86, with Edwin Krebs (Nobel Prize award 1992), he extensively characterized the M-phase specific Histone H1 kinase (which turned out to be CDK1/cyclin B). In the late ’80s, with Tim Hunt (Nobel Prize award 2001), he identified the CDK1 associated regulatory subunit as cyclin B. With Paul Greengard (Nobel Prize award 2000), he has been studying brain protein kinases and pharmacological inhibitors for three years (2001-2004) at the Rockefeller University (New York).

scut logo.jpg

Prof. Jun Wang

School of Medicine and South China University of Technology (SCUT)

Guangzhou, China

Professor Wang has actively conducted research on anticancer nanomedicine carriers and tumor microenvironment, and has made innovative academic achievements as systematically revealing the effect of nano characteristics of nano drug carriers on the in vivo fate; proposed and developed a new idea of drug carrier material design for activation within the acidic environment of tumor, and comprehensively overcoming multiple barrier to its delivery in vivo.

csm_Infrastructure_BNMRZ_logo_51c31f43a2_edited.jpg

Dr. Grzegorz Popowicz

The Bavarian NMR Center (BNMRZ)

Neuherberg, Germany

Group leader at The Bavarian NMR Center (BNMRZ), a joint research infrastructure of the Technical University of Munich (TUM) and the Helmholtz Center Munich (HMGU), with locations both at the Chemistry Department of TUM and the HMGU campus.

University_of_Tartu_logo_2.jpg

Prof. Asko Uri

Bioorganic Chemistry Department

University of Tartu

Tartu, Estonia

A leading scientist at the University of Tartu. Prof. Uri has been working in the field of protein kinase inhibition for more than 10 years. He has published various research papers and is an inventor for 3 pending patents.

LogoNorStruct-UiT 3.jpg

Prof. Richard Engh

The Norwegian Structural Biology Centre, NorStruct

The Arctic University of Norway, UiT

Tromsø, Norway

Professor and Head of the Department of Chemistry of the Arctic University of Norway. Prof. Engh's research interests are related to enzyme-ligand interactions - especially protein kinases, drug design, and cheminformatics.

LogoNorStruct-UiT 3.jpg

Dr. Ulli Rothweiler

The Norwegian Structural Biology Centre, NorStruct

The Arctic University of Norway, UiT

Tromsø, Norway

Researcher at the Department of Chemistry of the Arctic University of Norway.

map collaboration2.png
bottom of page